STRATA CRITICAL MEDICAL INC
SRTANASDAQTrading Snapshot
- Day Range
- $5.89 – $6.01
- 52-Week Range
- $3.69 – $6.50
- Volume
- $5.20B
- Avg Volume
- $4.80B
- Shares Outstanding
- 86.5M
- Next Earnings
- Sep 7, 2026
Fundamentals Snapshot
- Annual Revenue
- $197M
- Last Q Revenue
- $73M
- P/E Ratio
- 13.0
- P/S Ratio
- 2.0x
- EPS (TTM)
- $0.49
- Dividend Yield
- —
Why Investors Own SRTA
- ✓High-growth profile — revenue up +47.4% YoY with expanding US Equity exposure.
- ✓Healthy economics — 73% gross margin and 21% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About STRATA CRITICAL MEDICAL INC
Strata Critical Medical, Inc. is dedicated to supporting healthcare providers throughout the United States by offering swift logistical management and specialized medical assistance. A significant part of their operations involves the movement of human organs for transplant, utilizing both aerial and ground transportation methods. Founded in 2014, the organization previously operated under the name Blade Air Mobility, Inc. and is set to officially change its name to Strata Critical Medical, Inc. in August of 2025. Its primary corporate office is located in New York, New York.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Can Strata Critical Medical, Inc. (SRTA) Run Higher on Rising Earnings Estimates?
Strata Critical Medical, Inc. (SRTA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Strata Critical Medical, Inc. 2026 Q2 - Results - Earnings Call Presentation
2026-08-05. The following slide deck was published by Strata Critical Medical, Inc.
Strata Critical Medical, Inc. Q2 2026 Earnings Call Summary
Moby summary of Strata Critical Medical, Inc.'s Q2 2026 earnings call
Strata Critical Medical Inc (SRTA) (Q2 2026) Earnings Call Highlights: Revenue Surges 60. ...
Strata Critical Medical Inc (SRTA) boosts 2026 outlook after record Q2 performance driven by transplant services and strategic acquisitions.
Wall Street Analysts Predict a 60% Upside in Strata Critical Medical, Inc. (SRTA): Here's What You Should Know
The consensus price target hints at a 60% upside potential for Strata Critical Medical, Inc. (SRTA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Strata Critical Medical Announces Second Quarter 2026 Results
Revenue increased 60.7% year-over-year to $72.5 million in Q2 2026Clinical revenue increased 22.6% sequentially in Q2 2026; Excluding Clinical acquisitions that closed in Q2 2026, Clinical revenue increased 15.1% sequentially driven by a 23.8% increase in Transplant Clinical revenueQ2 2026 net loss from continuing operations of $(10.5) million or (14.5)% of revenueAdjusted EBITDA(1) of $7.9 million in Q2 2026; Adjusted EBITDA margin of 10.9%Cash flow from operating activities was $5.7 million in